Next-gen diagnostics are closing the care gap.
What’s happening: Australian biotech company Proteomics International plans to launch the world’s first blood test for endometriosis this year.
End game. In a peer-reviewed trial of 749 participants, Proteomics’ researchers identified 10 protein biomarkers associated with the chronic condition. Its PromarkerEndo blood test achieved 85%+ accuracy for early-stage detection and 99.7% accuracy for severe cases.
Pain point. Endometriosis affects roughly 1 in 10 women globally—approximately 190M individuals—yet remains severely underdiagnosed. Beyond pain, it can cause fertility and quality of life issues.
Taking seven years on average to pinpoint, earlier detection could allow for effective noninvasive therapies in place of surgery.
Looking ahead: With patents pending globally and an Australian launch imminent, Proteomics’ test looks to join the wave of breakthrough diagnostics advancing women’s health.
